Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2018 | Meeting Report

Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy

Authors: Maria Teresa Di Martino, Francesca Zazzeroni, Massimo Donadelli, Claudia Chiodoni, Michele Caraglia, Katia Scotlandi, Stefania Meschini, Carlo Leonetti

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2018

Excerpt

The 30^thAnnual Conference of Italian Association of Cell Cultures (AICC) was held at Fondazione IRCCS Istituto Nazionale dei Tumori, in Milan, on November 27–28, 2017, with the Scientific Coordination of Claudia Chiodoni and Mario Paolo Colombo, from the same Institute. The conference was opened by Katia Scotlandi, President of the Italian Association of Cell Cultures. The main objective of the conference was to discuss the present knowledge on the role of immune cells in the tumor microenvironment, shaped by cells promoting tumor survival that could be reeducated to treat cancer. The meeting was organized in two days with 5 thematic sessions, an opening and a closing lecture, with national and international speakers. The organizers truly thank those who took part in the conference and made the Conference a success. …

Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, WyserRmili C, Kiialainen A, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017; https://doi.org/10.1126/scitranslmed.aak9670.

Baer C, Squadrito ML, Laoui D, Thompson D, Hansen SK, Kiialainen A, et al. Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity. Nat Cell Biol. 2016; https://doi.org/10.1038/ncb337.

Ricci C, Mota C, Moscato S, D'Alessandro D, Ugel S, Sartoris S, et al. Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. Biomatter. 2014; https://doi.org/10.4161/21592527.2014.955386.

Jeon JS, Bersini S, Gilardi M, Dubini G, Charest JL, Moretti M, et al. Human 3D vascularized organo typic microfluidic assays to study breast cancer cell extravasation. Proc Natl Acad Sci U S A. 2015;112:214–9.CrossRefPubMed

Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.

Indraccolo S. Vascular endothelial growth factor blockade elicits a stable metabolic shift in tumor cells: therapeutic implications. Mol Cell Oncol. 2015; https://doi.org/10.1080/23723556.2015.1008307.

Caffa I, D'Agostino V, Damonte P, Soncini D, Cea M, Monacelli F, et al. Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. Oncotarget. 2015;6:11820–32.CrossRefPubMedPubMedCentral

Bellenghi M, Puglisi R, Pedini F, De Feo A, Felicetti F, Bottero L, et al. SCD5-induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin. J Pathol. 2015; https://doi.org/10.1002/path.4535.

Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen SS, et al. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv. 2016; https://doi.org/10.1182/bloodadvances.2016000984.

10.

Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S, et al. Diffuse large B-cell lymphomageno typing on the liquid biopsy. Blood. 2017; https://doi.org/10.1182/blood-2016-05-719641.

11.

Hess Michelini R, Freschi M, Manzo T, Jachetti E, Degl'Innocenti E, Grioni M, et al. Concomitant tumor and minor histocompatibility antigen-specific immunity initiaterejection and maintain remission from established spontaneous solid tumors. Cancer Res. 2010; https://doi.org/10.1158/0008-5472.CAN-09-4253.

12.

Manzo T, Sturmheit T, Basso V, Petrozziello E, Hess Michelini R, Riba M, et al. T cells redirected to a minor histocompatibility antigen instruct Intratumoral TNFa expression and empower adoptive cell therapy for solid tumors. Cancer Res. 2017; https://doi.org/10.1158/0008-5472.CAN-16-0725.

13.

Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, et al. Innovative therapy, monoclonal antibodies and beyond. Cytokine Growth Factor Rev. 2017; https://doi.org/10.1016/j.cytogfr.2017.10.002.

14.

Camisaschi C, Vallacchi V, Vergani E, Tazzari M, Ferro S, Tuccitto A, et al. Targeting immune regulatory networks to counteract immune suppression in cancer. Vaccines (Basel). 2016;4(4):pii: E38.CrossRef

15.

Sica A, Strauss L, Consonni FM, Travelli C, Genazzani A, Porta C. Metabolic regulation of suppressive myeloid cells in cancer. Cytokine Growth Factor Rev. 2017; https://doi.org/10.1016/j.cytogfr.2017.05.002.

16.

Sangaletti S, Tripodo C, Santangelo A, Castioni N, Portararo P, Gulino A, et al. Mesenchymal transition of high-grade breast carcinomas depends on extracellular matrix control of myeloid suppressor cell activity. Cell Rep. 2016; https://doi.org/10.1016/j.celrep.2016.08.075.

17.

Piconese S, Timperi E, Pacella I, Schinzari V, Tripodo C, Rossi M, et al. Human OX40 tunes the function of regulatory T cells in tumor and non tumor areas of hepatitis C virus-infected liver tissue. Hepatology. 2014; https://doi.org/10.1002/hep.27188.

18.

Stavropoulou V, Kaspar S, Brault L, Sanders MA, Juge S, Morettini S, et al. MLL-AF9 expression in hematopoietic stem cells drives a highly invasive AML expressing EMT-related genes linked to poor outcome. Cancer Cell. 2016; https://doi.org/10.1016/j.ccell.2016.05.011.

19.

De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017; https://doi.org/10.1038/nrc.2017.51.

Title: Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy
Authors: Maria Teresa Di Martino
Francesca Zazzeroni
Massimo Donadelli
Claudia Chiodoni
Michele Caraglia
Katia Scotlandi
Stefania Meschini
Carlo Leonetti
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2018
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-018-0710-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

Emerging role of lipid metabolism alterations in Cancer stem cells

Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side

Osthole inhibits triple negative breast cancer cells by suppressing STAT3

The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer

Correction to: Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours

The viable circulating tumor cells with cancer stem cells feature, where is the way out?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer